- Cytokinetics Incorporated (NASDAQ:CYTK) presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM).
- At ten weeks, patients in Cohort 4 experienced significant improvements in NT-proBNP, with an average decrease of 66%.
- High-sensitivity troponin I level also improved significantly proportional to baseline at each study visit.
- Related: FDA Rejects Cytokinetics’ Heart Failure Treatment Candidate.
- An improvement of ≥1 NYHA Functional Class was observed in 22 of 41 (54%) patients.
- After the 2-week washout period, NT-proBNP and high-sensitivity troponin I levels returned to baseline.
- Additionally, 48-week data from the FOREST-HCM study were also presented at the meeting.
- New data through 48 weeks of treatment showed that aficamten was associated with significant reductions in the average resting LVOT-G (mean change from baseline (SD) = -32 (28) mmHg, and Valsalva LVOT-G (mean change from baseline (SD) = -47 (28) mmHg.
- Treatment with aficamten also resulted in significant improvements in NYHA class, with 88% of patients experiencing a ≥1 NYHA Functional Class improvement, and significant improvements in NT-proBNP, with an average decrease of 70% from baseline to Week 48.
- Price Action: CYTK shares closed at $41.95 on Friday.
Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle
Cytokinetics Incorporated (NASDAQ:CYTK) presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). At…
Related Posts
WillScot Mobile Mini Acquires Rental Assets Of Hecht Trailers In New Jersey
WillScot Mobile Mini Holdings Corp (NASDAQ:WSC) closed the acquisition of the rental assets of Hecht Trailers in New Jersey, adding over…
Insulet Acquires Assets Related To Bigfoot’s Pump-based Automated Insulin Delivery Technologies For $25M, Including Certain Bigfoot Patents Related To Pumps That May Be Used For Automated Insulin Delivery Therapy
The transaction further strengthens Insulet's intellectual property (IP) portfolio and provides Bigfoot with additional capital to expand its Bigfoot Unity® Diabetes Management System to more people in need of
SVB Leerink Maintains Outperform on Natera, Raises Price Target to $160
SVB Leerink analyst Puneet Souda maintains Natera (NASDAQ:NTRA) with a Outperform and raises the price target from $140 to $160.